Urinary NGAL Ratio Is Not a Sensitive Biomarker for Monitoring Acute Tubular Injury in Kidney Transplant Patients: NGAL and ATI in Renal Transplant Patients
Table 1
Demographic and clinical data of patients with and without ATI.
ATI
ATI+
All patients
value
Recipient
Age (years)
49 ± 12 (49,20–69)
51 ± 12 (52,25–73)
51 ± 12 (50,20–73)
Gender (% m/f)
65,7/34,3
61,9/38,1
62,9/37,1
Retransplanted pat. (%)
8,6
10,5
10,0
Preformed antibodies neg. (%)
94,3
93,3
93,5
Lowest s-creatinine within the first 6 weeks of tx
160 ± 83
182 ± 87
176 ± 86
Hypercholesteroemia before tx (%)
31,4
37,1
35,7
Arterial hypertension before tx (%)
100
96,2
97,1
Donor
Age (years)
47 ± 15 (50,7−70)
51 ± 13 (52,16–77)
50 ± 14 (51,7–77)
Gender (% m/f)
60/40
53,3/46,7
55/45
Type
Deceased (%)
82,9
95,2
92,1
0.029
Living (%)
17,1
4,8
7,9
CMV IgG positive (%)
60
53,8
55,4
s-creatinine (μmol/L)
95 ± 36
93 ± 44
93 ± 42
Graft factors at tx
Cold ischemia time (h)
14 ± 7
17 ± 7
17 ± 7
0.032
Mean number of HLA mismatches
2,26 ± 1,6
2,4 ± 1,72
2,36 ± 1,68
Initial function of the graft (%)
68,6
28,6
38,6
0.000
Need of dialysis following tx (%)
31,4
71,4
62,1
0.000
Immunosuppressive regimen (%)
CyA-MMF-Steroids-IL2
37,1
31
32,6
CyA-MMF-Steroids-ATG
0
1
0,7
CyA-MMF-Steroids-no induction
0
3
2,2
CyA-MMF-IL2
14,3
31
26,7
CyA-MMF-ATG
0
1
0,7
Other, IL2
28,6
14
17,8
Other, ATG
11,4
7
8,1
Other, no induction
8,6
12
11,1
ATI−: patients without ATI; ATI+: patients with ATI; tx: transplantation; median and range of values in brackets; CyA: cyclosporine A; MMF: mycophenolate mofetil; ATG: antithymocyte globulin; IL2: interleukin 2 receptor antagonist.
